Related Experiment Video
Updated: Apr 1, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With
Naoki Misumida1, Kishore Harjai2, Steven Kernis3
1Department of Internal Medicine, Mount Sinai Beth Israel, New York, NY, USA misumidanaoki@gmail.com.
Insights
Oral beta-blocker therapy reduces long-term mortality in ST-segment elevation myocardial infarction (STEMI) patients with preserved left ventricular ejection fraction (LVEF) after primary percutaneous coronary intervention (PCI). This finding supports current guideline recommendations.
Area of Science:
- Cardiology
- Clinical Research
- Pharmacotherapy
Background:
- Long-term mortality effects of oral beta-blockers in ST-segment elevation myocardial infarction (STEMI) patients with preserved left ventricular ejection fraction (LVEF) post-primary percutaneous coronary intervention (PCI) are not well-defined.
- Existing guidelines recommend beta-blocker use, but evidence in this specific patient subgroup requires clarification.
Purpose of the Study:
- To evaluate the association between oral beta-blocker therapy and long-term mortality in STEMI patients with preserved LVEF undergoing primary PCI.
- To synthesize evidence from available studies to inform clinical practice and guideline adherence.
Main Methods:
- A systematic search of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials was conducted.
- Included were observational studies with adjusted hazard ratios and follow-up ≥6 months; no randomized controlled trials met criteria.
- A random-effects model was used to pool hazard ratios for all-cause mortality.
Main Results:
- Seven observational studies comprising 10,857 patients were analyzed, with follow-up ranging from 6 months to 5.2 years.
- Oral beta-blocker therapy was associated with a significant reduction in all-cause mortality (pooled hazard ratio 0.79, 95% CI 0.65-0.97).
- Preserved LVEF was defined as ≥40% in four studies and ≥50% in three studies.
Conclusions:
- Oral beta-blocker therapy is linked to decreased all-cause mortality in STEMI patients with preserved LVEF treated with primary PCI.
- These findings support the continued use of oral beta-blockers in this patient population as per current guidelines.
- The study underscores the importance of beta-blocker therapy for improving outcomes in STEMI survivors with preserved cardiac function.
Background:
The effect of oral beta-blocker therapy on long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who are treated with primary percutaneous coronary intervention (PCI) and who have preserved left ventricular ejection fraction (LVEF) remains unclear.
Methods:
We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies evaluating the effect of oral beta-blocker therapy in patients with STEMI who underwent primary PCI and who had preserved LVEF. The primary outcome was all-cause mortality. Randomized controlled trials and the observational studies that reported an adjusted hazard ratio (or hazard ratio in the propensity score-matched patients) with follow-up duration equal to or more than 6 months were included. Pooled hazard ratio with 95% confidence interval (CI) was calculated using a random effect model.
Results:
No randomized controlled trials met the inclusion criteria. Seven observational studies totaling 10 857 patients met the inclusion criteria. Follow-up duration ranged from 6 months to 5.2 years. Preserved LVEF was defined as 40% in 4 studies and 50% in 3 studies. Based on the pooled estimate, oral beta-blocker therapy was associated with a reduction in all-cause mortality (combined hazard ratio 0.79, 95% CI 0.65-0.97).
Conclusion:
This meta-analysis demonstrates that oral beta-blocker therapy is associated with decreased all-cause mortality in patients with STEMI who are treated with primary PCI and who have preserved LVEF. This supports the current American College of Cardiology Foundation/American Heart Association 2013 Guideline for the Management of STEMI.
